Semaglutide, a long-acting GLP-1 analogue, for the management of early-onset obesity due to MC4R defect: a case report
Food and Drug Administration first approved some forms of GLP-1s for treating type 2 diabetes in 2005, its more recent approval as a weight loss drug, coupled with its increasing popularity, draws probable correlations between the drug and Gallup's obesity rate findings
How to Choose the Right Skin Care Products Containing This Peptide Not all skin care products featuring peptides are equally effective
Offers Microdose GLP-1 programs that start at lower doses and use slower, personalized titration to manage observable side effects and tolerance
Both are dominated by dose-related gastrointestinal effects (nausea, diarrhea, constipation)
GLP-1s are now FDA-approved to treat many conditions, including obesity, obstructive sleep apnea, and metabolic-associated steatohepatitis